Get the Stockscreener App
787.15
1.95%
-16.01
Regeneron Pharmaceuticals Inc stock is traded at $787.15, with a volume of 254.01K.
It is down -1.95% in the last 24 hours and up +7.43% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$803.17
Open:
$803.475
24h Volume:
254.01K
Relative Volume:
0.27
Market Cap:
$83.22B
Revenue:
$14.34B
Net Income/Loss:
$4.50B
P/E Ratio:
18.94
EPS:
41.5626
Net Cash Flow:
$3.77B
1W Performance:
+4.32%
1M Performance:
+7.43%
6M Performance:
+35.68%
1Y Performance:
+16.91%
1-Day Range:
$786.43
$815.00
1-Week Range:
$745.07
$815.00
52-Week Range:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
787.18 | 84.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.17 | 124.83B | 12.07B | 3.95B | 3.19B | 15.33 |
|
ARGX
Argen X Se Adr
|
839.57 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.13 | 41.70B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
350.61 | 38.30B | 4.98B | 69.60M | 525.67M | 0.5198 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
NEOS Investment Management LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
GSA Capital Partners LLP Purchases 1,358 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Price Over Earnings Overview: Regeneron PharmaceuticalsRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga
Assetmark Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why is Regeneron Pharmaceuticals Inc. stock going downTrade Exit Report & AI Optimized Trade Strategies - mfd.ru
Aberdeen Group plc Sells 52,247 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (NASDAQ:REGN) Performance Challenges Broader Nasdaq Futures Volatility - Kalkine Media
Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by Wall Street Zen to Hold - MarketBeat
Market Review: What are the future prospects of Regeneron Pharmaceuticals IncMarket Volume Report & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Caprock Group LLC Takes $1.47 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron Pharmaceuticals Inc. attractive at current valuationJuly 2025 Intraday Action & Expert Curated Trade Setup Alerts - mfd.ru
Is Regeneron Pharmaceuticals Inc. (RGO) stock in buy zone after pullback2025 Analyst Calls & High Accuracy Investment Signals - mfd.ru
Varma Mutual Pension Insurance Co Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Wealthfront Advisers LLC - MarketBeat
LSV Asset Management Takes $31.26 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cibc World Market Inc. Has $8.85 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Allergy Data And Dupixent Insights Shape Immunology Growth Story - simplywall.st
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
Regeneron Allergy Antibodies And Dupixent Data Reframe Growth Prospects - Yahoo Finance
Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts? - Bitget
HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating - marketscreener.com
Krilogy Financial LLC Invests $1.18 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Illinois Municipal Retirement Fund Buys 2,599 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron, Samsung Bioepis Settle Eylea Biosimilar Patent Case - Bloomberg Law News
10 Best Medical Research Stocks to Buy According to Hedge Funds - Insider Monkey
Regeneron, Samsung Bioepis Settle Eye Med Patent Claims - Law360
Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial - TipRanks
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026? - Yahoo Finance
Rhumbline Advisers Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Leuthold Group LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
115,028 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Sound Shore Management Inc CT - MarketBeat
Prospera Financial Services Inc Has $4.93 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Block Graft Market Is Going to Boom | Regeneron Pharmaceuticals • Novartis • Pfizer - openPR.com
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges - Finviz
Samsung Bioepis to launch ophthalmology biosimilar in U.S. next year - Yonhap News Agency
Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $77,853.00 in Stock - MarketBeat
Insider Selling: Arthur Ryan Sells Shares of Regeneron Pharmaceu - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) SVP Sells $1,585,066.72 in Stock - MarketBeat
How to watch Regeneron's March healthcare investor talks - Stock Titan
Regeneron Announces Investor Conference Presentations - The Manila Times
Regeneron Pharmaceuticals Officer Sells Over $1.5 Million in Company Stock - TradingView
A Look At Regeneron (REGN) Valuation As Recent Share Weakness Meets An 8.1% Undervaluation Estimate - simplywall.st
Trading Systems Reacting to (REGN) Volatility - Stock Traders Daily
Skylands Capital LLC Acquires New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ING Groep NV Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Baader Bank Aktiengesellschaft - MarketBeat
The Zacks Analyst Blog Highlights NVIDIA, Amazon.com, Regeneron, National Presto and AXIL - Nasdaq
Regeneron to present Phase 3 data on novel allergy antibodies at AAAAI - Investing.com South Africa
Evommune’s Atopic Dermatitis Data Competitive With Dupixent - Citeline News & Insights
The Bull Case For Regeneron (REGN) Could Change Following New Allergy Antibody And Dupixent Data Unveiling - Yahoo Finance
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.91%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):